These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33684953)

  • 1. Thymoquinone with Metformin Decreases Fasting, Post Prandial Glucose, and HbA1c in Type 2 Diabetic Patients.
    Ali SM; Chen P; Sheikh S; Ahmad A; Ahmad M; Paithankar M; Desai B; Patel P; Khan M; Chaturvedi A; Patel R; Panchal DT; Shah K; Chavda V; Saboo BD; Patel A; Ahmad I
    Drug Res (Stuttg); 2021 Jul; 71(6):302-306. PubMed ID: 33684953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.
    Raskin P; Lewin A; Reinhardt R; Lyness W;
    Diabetes Obes Metab; 2009 Sep; 11(9):865-73. PubMed ID: 19476470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of antihyperglycemic activity of nano-thymoquinone in rat model of type-2 diabetes.
    Rani R; Dahiya S; Dhingra D; Dilbaghi N; Kim KH; Kumar S
    Chem Biol Interact; 2018 Nov; 295():119-132. PubMed ID: 29421519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.
    Brunetti P; Pagano G; Turco C; Gori M; Perriello G;
    Diabetes Nutr Metab; 2004 Dec; 17(6):350-7. PubMed ID: 15887629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
    Raskin P; Lewin A; Reinhardt R; Lyness W;
    Diabetes Obes Metab; 2009 Oct; 11(10):947-52. PubMed ID: 19531054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
    Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic activity enhancement in streptozotocin + nicotinamide-induced diabetic rats through combinational polymeric nanoformulation.
    Rani R; Dahiya S; Dhingra D; Dilbaghi N; Kaushik A; Kim KH; Kumar S
    Int J Nanomedicine; 2019; 14():4383-4395. PubMed ID: 31354267
    [No Abstract]   [Full Text] [Related]  

  • 10. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
    Fujioka K; Pans M; Joyal S
    Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Clinical Efficacy and Safety of Metformin Sustained-Release Tablet (II) (Dulening) and Metformin Tablet (Glucophage) in Treatment of Type 2 Diabetes Mellitus.
    Guo LX; Liu GE; Chen L; Wang HF; Guo J; Zheng XL; Duan BH; Wang DZ; Zhu W; Wang K; Tan WS; Chen Q; Li QZ; Yang J; Zhang Q; Xie PF; Lei MX
    Front Endocrinol (Lausanne); 2021; 12():712200. PubMed ID: 34659110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans.
    Nath S; Ghosh SK; Choudhury Y
    J Pharmacol Toxicol Methods; 2017; 84():20-30. PubMed ID: 27773844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
    Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
    Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes.
    Chien HH; Chang CT; Chu NF; Hsieh SH; Huang YY; Lee IT; Lee WJ; Tang YJ; Sheu WH
    J Chin Med Assoc; 2007 Nov; 70(11):473-80. PubMed ID: 18063500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents: value of evening blood glucose determination.
    Guillausseau PJ
    Diabet Med; 1997 Sep; 14(9):798-802. PubMed ID: 9300232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
    Garber AJ; Bruce S; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice.
    Vähätalo M; Rönnemaa T; Viikari J
    Scand J Prim Health Care; 2007 Sep; 25(3):147-53. PubMed ID: 17846932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.